Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Ibrutinib and Venetoclax for First-Line Treatment of CLL

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Epigenetic therapy in hematological cancers

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

The main objectives of the present study were to monitor minimal residual disease (MRD) in the bone marrow of patients with mantle cell lymphoma (MCL) to predict clinical relapse and guide preemptive treatment with rituximab. Among the patients enrolled in 2 prospective trials by the Nordic Lymphoma Group, 183 who had completed autologous stem cell transplantation (ASCT) and in whom an MRD marker had been obtained were included in the our analysis. Fresh samples of bone marrow were analyzed for MRD by a combined standard nested and quantitative real-time PCR assay for Bcl-1/immunoglobulin heavy chain gene (IgH) and clonal IgH rearrangements. Significantly shorter progression-free survival (PFS) and overall survival (OS) was demonstrated for patients who were MRD positive pre-ASCT (54 patients) or in the first analysis post-ASCT (23 patients). The median PFS was only 20 months in those who were MRD-positive in the first sample post-ASCT, compared with 142 months in the MRD-negative group (P < .0001). OS was 75% at 10 years and median not reached in the MRD-negative group, compared with only 35 months in the MRD-positive group (P < .0001). Of the 86 patients (47%) who remained in continuous molecular remission, 73% were still in clinical remission after 10 years. For all patients, the median time from ASCT to first molecular relapse was 55 months, with a continuous occurrence of late molecular relapses. Fifty-eight patients who experienced MRD relapse received rituximab as preemptive treatment on 1 or more occasions, and in this group, the median time from first molecular relapse to clinical relapse was 55 months. In most cases, rituximab converted patients to MRD negativity (87%), but many patients became MRD-positive again later during follow-up (69%). By multivariate analysis, high-risk Mantle Cell Lymphoma International Prognostic Index score and positive MRD status pre-ASCT predicted early molecular relapse. In conclusion, preemptive rituximab treatment converts patients to MRD negativity and likely postpones clinical relapse. Molecular monitoring offers an opportunity to select some patients for therapeutic intervention and to avoid unnecessary treatment in others. MRD-positive patients in the first analysis post-ASCT have a dismal prognosis and thus are in need of novel strategies.

OriginalsprogEngelsk
TidsskriftBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Vol/bind23
Udgave nummer3
Sider (fra-til)428-435
ISSN1083-8791
DOI
StatusUdgivet - 2017

ID: 49676970